 Ligand Pharmaceuticals Incorporated NASDAQ: LGND announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately 133 million and diluted EPS to be 3.62, up from previous guidance for total revenues of approximately 128 